Stockreport

Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026 [Yahoo! Finance]

Nuvation Bio Inc. Class A  (NUVB) 
PDF IBTROZI also demonstrated a high overall response rate in TKI-naïve patients at 89.8% Long-term pooled data highlighted in oral and poster presentations at AACR, and [Read more]